Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript

Prestige Healthcare (PBH) reported Q2 2027 earnings, with revenue up 23% to $336.3M, driven by acquisitions and organic growth. Adjusted EPS rose 6% to $1.13. The company integrated Breathe Right and LaCorium, expecting long-term growth. eCommerce sales grew mid-teens, with investments in digital media and content.

Original reporting
Published Nov 5, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prestige Healthcare (PBH) Q2 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$PBHBullishMed
01

Why it matters

The earnings release confirms successful integration and revenue contribution from the new brands, reinforcing the company's growth strategy.

02

Market read

First‑time earnings disclosure with strong top‑line growth, likely to move PBH stock and influence the consumer health sector.

03

What to watch

The modest decline in adjusted free cash flow and higher interest expense could limit near‑term cash generation.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

Prestige Healthcare recently completed the Breathe Right and LaCorium acquisitions, integrating them into its portfolio.

Company-level read

Ticker impact

$PBHBullishHigh confidence
Context

Q2 2027 earnings call disclosed revenue of $336.3M (+22.7% YoY) and adjusted EPS of $1.13, marking the first public release of these figures.

Expected impact

likely upward pressure as market prices in the earnings beat and improved outlook.

Evidence & confidence

The company reported better-than-expected top line and EPS, and announced debt reduction plans, which typically support a positive price reaction.

Market effects

Highlights growth potential in consumer health and over‑the‑counter therapeutic brands, possibly boosting peer valuations.

Strong performance in North America and international segments may lift related health‑care stocks.

Adds to the broader narrative of resilient consumer health demand amid inflationary pressures.

Counterpoint

If integration costs or debt servicing pressures materialize, the stock could face downside despite the earnings beat.

Key entities

  • Prestige Healthcare

    US‑listed consumer health company reporting Q2 2027 results.

Related articles

$PBHMed

Prestige Consumer Healthcare Q2 Earnings Call Highlights

Prestige Consumer Healthcare (PBH) lowered its full-year Clear Eyes sales forecast to under $20M, citing production issues. Q3 revenue is expected at $328M with EPS of $1.05. Recent acquisitions Breathe Right and LaCorium contributed $71M in H1 revenue. The company plans to prioritize debt reduction, with net debt at $2.1B. E-commerce sales growth continues at a mid-teens rate.

$PBHMed

Prestige Consumer Healthcare Inc (PBH) (Q2 2027) Earnings Call Highlights: Revenue Surges

Prestige Consumer Healthcare (PBH) reported Q2 2027 revenue growth of 23%, with EBITDA margin at 34%. The company prioritized debt reduction, leaving $90M in share repurchase authorization. Organic brands performed well, with GI brands benefiting from GLP-1 marketing. Women's Health saw slight quarterly growth but year-to-date decline. Acquisitions Breathe Right and Liquorium showed strong early results.